SynthesisBMC pulmonary medicine2020
The global impact of Aspergillus infection on COPD.
Synthesis in BMC pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 98 citations in OpenAlex.
- Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.American journal of respiratory and critical care medicine · 2026Article
- Risk factors for intensive care unit coronavirus disease 2019 pneumonia-associated invasive fungal infections: a Bayesian evidence synthesis integrating external and real-world data.Virology journal · 2026Article
- Article
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Multiplex on-chip detection ofFrontiers in bioengineering and biotechnology · 2026Article
- Association betweenFrontiers in immunology · 2026Article
- Aspergillus sensitisation & allergic bronchopulmonary aspergillosis in chronic obstructive pulmonary disease: Redefining a treatable trait.The Indian journal of medical research · 2025Article
- Estimated burden of serious mycoses in Poland.Scientific reports · 2025Article
- Unlocking the Secrets: Causal Associations Between Blood Metabolites and Aspergillosis.Current microbiology · 2025Article
- Emerging Risk Factors for Invasive Pulmonary Aspergillosis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Article
- Human immunity to fungal infections.The Journal of experimental medicine · 2025Review
- Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.American journal of respiratory and critical care medicine · 2025Article
- Epidemiology and risk factors of fungal pathogens in sepsis: a prospective nationwide multicenter cohort study.BMC infectious diseases · 2025Article
- Aspergillus fumigatus is responsible for inflammation in a murine model of chronic obstructive pulmonary disease exacerbation.Respiratory research · 2025Article
- Correlation ofInternational journal of chronic obstructive pulmonary disease · 2025Article
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- Non-invasive monitoring ofFrontiers in cellular and infection microbiology · 2025Observational
- Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance.Nature communications · 2024Article
- Multi-scale Lesion Feature Fusion and Location-Aware for Chest Multi-disease Detection.Journal of imaging informatics in medicine · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced chronic obstructive pulmonary disease (COPD) often leads to hospitalisation and invasive aspergillosis (IA) is a serious complication. Aspergillus sensitisation may worsen symptoms in COPD.
methodsWe identified published papers between January 2000 and May 2019 with > 50 subjects and GOLD criteria for grade II, III or IV (FEV1/FVC < 70% and FEV1 < 80%) using standardised criteria in multiple countries, to re-estimate the prevalence of COPD. Hospitalised COPD patients develop IA in 1.3-3.9%, based on positive cultures of Aspergillus spp. and radiological findings. Given limited data on per-patient annual hospitalisation rates, we assumed a conservative 10.5% estimate. Annual IA mortality in COPD was estimated using the literature rates of 43-72%. A separate literature search assessed the impact of Aspergillus sensitisation on severity of COPD (by FEV1).
resultsWe re-estimated the global prevalence of COPD GOLD stages II-IV at 552,300,599 people (7.39% of the population) with 339,206,893 (8.58%) in Asia, 85,278,783 (8.52%) in the Americas, 64,298,051 (5.37%) in Africa, 59,484,329 (7.77%) in Europe and 4,032,543 (10.86%) in Oceania. An estimated 57,991,563 (10.5%) people with COPD are admitted to hospital annually and of these 753,073 (1.3%) - 2,272,322 (3.9%) develop IA and 540,451-977,082 deaths are predicted annually. Aspergillus sensitisation prevalence in COPD was 13.6% (7.0-18.3%) and not related to lower predicted FEV1% (P > 0.05).
conclusionsThe prevalence of COPD is much higher than previously estimated. Overall COPD mortality may be higher than estimated and IA probably contributes to many deaths. Improved rapid diagnosis of IA using culture and non-culture based techniques is required in COPD hospital admissions to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.